Article Text
Statistics from Altmetric.com
Commentary on: OpenUrl
Context
The National Lung Screening Trial (NLST) revealed a 20% reduction in lung cancer mortality from three annual low-dose CT screening scans compared with chest radiographs in high-risk individuals.1 Since up to 10 million individuals in the USA may qualify for annual CT screening, policymakers have legitimately questioned whether the benefits of lung cancer screening justify the potential high costs of large-scale screening implementation. To assess the value of CT screening, Black et al conducted a trial-based cost-effectiveness analysis using the NLST data.
Methods
This trial-based cost-effectiveness analysis compared life expectancy, quality-adjusted life expectancy (QALE) and lifetime costs for three strategies: (1) annual CT screening for 3 years; (2) annual chest X-ray screening for 3 years and (3) no screening. …
Footnotes
Competing interests None.
Provenance and peer review Commissioned; internally peer reviewed.